8-K/A: Liminatus Pharma Completes Business Combination, Faces Significant Financial Hurdles Despite Nasdaq Listing

Liminatus Pharma, Inc. has completed its business combination and commenced trading on Nasdaq, but the pre-clinical stage biopharmaceutical company faces substantial doubt about its ability to continue as a going concern due to significant accumulated losses and ongoing funding needs.

Summary

• Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) completed its business combination with Liminatus Pharma, LLC and Iris Acquisition Corp on April 30, 2025.
• The combined company's common stock (LIMN) and public warrants (LIMNW) began trading on The Nasdaq Stock Market LLC on May 1, 2025, following the cessation of trading for Iris Acquisition Corp's securities on the OTC Pink Marketplace.
• Liminatus Pharma, LLC, the operating entity, is a pre-clinical stage, pre-revenue life sciences company focused on developing a next-generation CD47 checkpoint inhibitor (IBA101) for solid cancers under an exclusive license agreement with InnoBation Bio Co. Ltd.
• The company reported a net loss of $0.3 million for the three months ended March 31, 2025, a significant improvement from a net loss of $1.8 million for the same period in 2024, primarily due to the termination of certain research and development licenses.
• As of March 31, 2025, Liminatus Pharma, LLC had an accumulated deficit of $29.0 million and a cash balance of approximately $35,000.
• The company has funded operations through $4.5 million from equity sales and $20.0 million from bonds and notes through December 31, 2024, with an additional $0.7 million in notes raised subsequent to December 31, 2024, and $3.6 million subsequent to March 31, 2025, primarily from related parties.
• Public stockholders of Iris Acquisition Corp redeemed 59,844 Class A Shares for approximately $702,359 (about $11.74 per share) in connection with the business combination.
• The company's CAR-T License and Vaccine License with TDT were terminated in August 2024, resulting in a decrease in research and development expenses but also a reduction in pipeline assets; negotiations are ongoing regarding $2.2 million owed to TDT.
• The PIPE Equity Investment of $15.0 million was remitted to the combined company upon closing of the business combination.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's pre-revenue status, significant accumulated losses, very low cash balance, and explicit 'going concern' warning. While the business combination and Nasdaq listing are positive steps, the underlying financial fragility and the need for substantial additional funding in the near term outweigh these, especially with the loss of pipeline assets from license terminations.

Positives

• Successful completion of the business combination and subsequent listing on The Nasdaq Stock Market LLC, providing access to a broader capital market.
• Significant reduction in net loss for Liminatus Pharma, LLC, from $1.8 million in Q1 2024 to $0.3 million in Q1 2025, primarily due to reduced R&D spending following license terminations.
• Secured an exclusive worldwide license for a next-generation CD47 immune checkpoint inhibitor, a promising area in oncology.
• Pro forma cash and cash equivalents of approximately $12.0 million post-Business Combination, providing some immediate liquidity.

Negatives

• Liminatus Pharma, LLC is a pre-revenue company with significant accumulated operating losses, totaling $29.0 million as of March 31, 2025.
• The company has a very low cash balance of approximately $35,000 as of March 31, 2025, indicating severe liquidity constraints prior to the business combination proceeds.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• Termination of the CAR-T License and Vaccine License with TDT in August 2024 reduces the company's product pipeline and future development opportunities, with $2.2 million still under negotiation as amounts due.
• High reliance on related-party debt, with $20.7 million in short-term debt as of March 31, 2025, much of which is past due but repayment deferred by mutual agreement.
• Iris Acquisition Corp experienced delisting from Nasdaq prior to the business combination due to non-compliance with listing rules and failure to timely file reports.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next twelve months.
• Inability to raise adequate additional capital on acceptable terms, which could lead to delays, reductions, or elimination of research and development programs or future commercialization efforts.
• Uncertainty regarding the timing, duration, and completion costs of preclinical studies and clinical trials for the CD47 product candidate.
• Risks related to obtaining regulatory approval for product candidates and the potential for product candidates not to achieve commercial success.
• Dependence on third-party contractors for clinical trials and manufacturing, with risks of non-compliance or failure to meet contractual obligations.
• Exposure to current and future conditions in the global economy, including economic uncertainty, inflation, and interest rates, which could impact the company's business and markets.
• Potential for dilution of existing members and shareholders if additional equity financing is pursued.
• Ongoing negotiations with TDT regarding the $2.2 million due following the termination of the CAR-T and Vaccine licenses, with uncertainty as to the final payment amount.
• Increased costs associated with operating as a public company, including compliance, legal, accounting, and administrative expenses.

Future Outlook

The company anticipates a significant increase in expenses as it progresses its CD47 product candidate through clinical trials, seeks regulatory approval, scales manufacturing, and establishes commercialization infrastructure. It also expects increased costs associated with operating as a public company. While the main filing states that the net proceeds from the Business Combination are expected to fund operations for at least the next twelve months, the more detailed financial discussion for Liminatus Pharma, LLC (Exhibit 99.6) explicitly states that these proceeds will NOT be sufficient to fund operating expenses and capital requirements through at least the next twelve months, indicating a strong need for substantial additional funding through equity or debt financings. The company acknowledges that identifying product candidates and conducting trials is a time-consuming, expensive, and uncertain process, and there is no assurance of generating revenue or achieving commercial success in the near term.

Management Comments

• Management's operations have focused on raising capital and entering into license and development agreements for conducting research and development activities for its products.
• Management anticipates that expenses will increase significantly in connection with ongoing activities, including conducting clinical trials, seeking regulatory approval, scaling capabilities, manufacturing, and establishing commercialization infrastructure.
• Management believes that all of its properties have been adequately maintained, are generally in good condition, and are suitable and adequate for its business.
• Management has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying unaudited condensed financial statements are issued.
• Management's plans to address the going concern issue include raising additional cash through equity financings, debt financings, or other arrangements to fund operations.

Industry Context

Liminatus Pharma operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on oncology with a pre-clinical stage CD47 immune checkpoint inhibitor. The CD47 pathway is a significant area of research in cancer immunotherapy, with several companies developing therapies to block the 'don't eat me' signal. Being a pre-clinical stage company, Liminatus faces inherent high risks and uncertainties common to early-stage biotech firms, including the long and expensive development timelines, regulatory hurdles, and the high probability of clinical trial failures. The termination of its CAR-T and Vaccine licenses indicates a narrowing of its pipeline focus, which is a strategic shift in a competitive landscape where diversified pipelines can offer more resilience.

Comparison to Industry Standards

• As a pre-clinical stage biopharmaceutical company, Liminatus Pharma is typical in its lack of revenue and reliance on external financing for research and development.
• The company's accumulated deficit of $29.0 million and low cash balance of $35,000 as of March 31, 2025, are indicative of the significant capital burn rate common in early-stage drug development, though the 'substantial doubt about going concern' is a critical red flag.
• The termination of two key license agreements (CAR-T and Vaccine) is a notable deviation from a diversified pipeline strategy, which some larger or more established biotech firms might maintain to spread risk.
• The high proportion of related-party debt ($20.7 million) suggests challenges in securing non-related party financing, which is not uncommon for early-stage companies but can raise governance and financial stability concerns compared to companies with broader investor bases.

Corporate Governance

Legal Proceedings

• The Company is not a party to any material legal proceedings and is not aware of any material pending or threatened claims.

Related Party Transactions

• Liminatus Pharma, LLC has significant outstanding debt with related parties, including Feelux Co., Ltd. ($10.0M bonds), Car-Tcellkor, Inc. ($0.8M loan), Valetudo Therapeutics LLC ($2.8M loans), Ewon Comfortech Co., Ltd. ($3.2M loans), Prophase Sciences LLC ($2.0M loans as of March 31, 2025, plus $3.6M subsequent), and Hana Immunotherapeutics, LLC ($0.9M loans), and Amantes LLC ($1.0M loans).
• Many of these related-party loans are past due, but repayment has been mutually deferred until the completion of the Business Combination.
• Liminatus Pharma, LLC has a loan receivable from Iris Acquisition Corp totaling $4.2 million as of March 31, 2025, which was netted upon the business combination.
• Liminatus Pharma, LLC owes $0.2 million to its CEO for compensation.
• Iris Acquisition Corp had promissory notes outstanding to its Sponsor ($1.5 million) and Liminatus ($4.2 million) as of March 31, 2025.
• Iris Acquisition Corp entered into an administrative support agreement with Arrow Capital Management LLC, a related party, for office space and support, with payments of $30,000 per month from September 1, 2024.
• Hana Immunotherapeutics, LLC, an affiliate of Liminatus's CEO, loaned approximately $1.216 million to Gaius Investment Partners, the buyer of the managing member of Iris's Sponsor.

Stakeholder Impact

• Shareholders: The business combination and Nasdaq listing offer potential for increased liquidity and market visibility, but the substantial doubt about going concern and the need for future capital raises pose significant dilution risks and uncertainty regarding long-term value creation.
• Employees: The company's focus on advancing its CD47 product and scaling operations suggests potential for growth and new hires, but the financial instability could impact job security.
• Customers: As a pre-revenue, pre-clinical company, there are no current product customers; future customers depend entirely on successful product development and regulatory approval.
• Suppliers/Creditors: Related-party creditors have deferred repayment of significant debt, indicating a reliance on their continued support. Non-related party creditors face risks due to the company's going concern issues.
• Regulatory Authorities: The company's status as an emerging growth company allows for reduced reporting burdens, but it must still comply with SEC and Nasdaq requirements, which will incur additional costs.

Next Steps

• Conduct clinical trials for the CD47 product candidate and initiate/complete additional trials for future potential product candidates.
• Seek regulatory approval for any product candidates that successfully complete clinical trials.
• Scale up clinical and regulatory capabilities.
• Manufacture materials for clinical trials and potential commercial sales.
• Establish a commercialization infrastructure and scale up manufacturing and distribution capabilities.
• Adapt regulatory compliance efforts for marketed products.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional clinical, manufacturing quality control, regulatory, manufacturing, scientific, and administrative personnel.
• Add operational, financial, and management information systems and personnel.
• Incur additional legal, accounting, and other expenses associated with operating as a public company.
• Repay existing debt, particularly the $20.7 million in short-term related-party loans.
• Raise substantial additional capital through equity or debt financings to fund ongoing operations and development.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Oncology, CD47 checkpoint inhibitor, Pre-clinical stage, SEC filing, Business Combination, SPAC, Nasdaq listing, Going concern, Drug development, Clinical trials, License agreement, Related party debt, Financial reporting